Phaseline

Companies › Neutron Therapeutics

Neutron Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
L-Boronophenylalanine (L-BPA) complexed with fructose
Boron carrier molecule for neutron capture therapy; complexed with fructose to increase so
–Phase 1Head and Neck Carcinoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07058116L-Boronophenylalanine (L-BPA) complexed with fructosePhase 1Head and Neck CarcinomaOncologyNov 2025

From the company's SEC filings

Cash of $278m on 2026-06-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.